Metabolic reprogramming by immune-responsive gene 1 up-regulation improves donor heart preservation and function
- 8 February 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (682) , eade3782
Abstract
Preservation quality of donor hearts is a key determinant of transplant success. Preservation duration beyond 4 hours is associated with primary graft dysfunction (PGD). Given transport time constraints, geographical limitations exist for donor-recipient matching, leading to donor heart underutilization. Here, we showed that metabolic reprogramming through up-regulation of the enzyme immune response gene 1 (IRG1) and its product itaconate improved heart function after prolonged preservation. Irg1 transcript induction was achieved by adding the histone deacetylase (HDAC) inhibitor valproic acid (VPA) to a histidine-tryptophan-ketoglutarate solution used for donor heart preservation. VPA increased acetylated H3K27 occupancy at the IRG1 enhancer and IRG1 transcript expression in human donor hearts. IRG1 converts aconitate to itaconate, which has both anti-inflammatory and antioxidant properties. Accordingly, our studies showed that Irg1 transcript up-regulation by VPA treatment increased nuclear translocation of nuclear factor erythroid 2–related factor 2 (Nrf2) in mice, which was accompanied by increased antioxidant protein expression [hemeoxygenase 1 (HO1) and superoxide dismutase 1 (SOD1)]. Deletion of Irg1 in mice (Irg1 −/− ) negated the antioxidant and cardioprotective effects of VPA. Consistent with itaconate’s ability to inhibit succinate dehydrogenase, VPA treatment of human hearts increased itaconate availability and reduced succinate accumulation during preservation. VPA similarly increased IRG1 expression in pig donor hearts and improved its function in an ex vivo cardiac perfusion system both at the clinical 4-hour preservation threshold and at 10 hours. These results suggest that augmentation of cardioprotective immune-metabolomic pathways may be a promising therapeutic strategy for improving donor heart function in transplantation.Keywords
This publication has 62 references indexed in Scilit:
- Epigenetic Mechanisms in Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2013
- Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptideBritish Journal of Cancer, 2011
- Energy Metabolism in H460 Lung Cancer Cells: Effects of Histone Deacetylase InhibitorsPLOS ONE, 2011
- Complement dependency of cardiomyocyte release of mediators during sepsisThe FASEB Journal, 2011
- Metabolism as a key to histone deacetylase inhibitionCritical Reviews in Biochemistry and Molecular Biology, 2011
- Glucose Metabolism as a Target of Histone Deacetylase InhibitorsMolecular Endocrinology, 2009
- The many roles of histone deacetylases in development and physiology: implications for disease and therapyNature Reviews Genetics, 2009
- Myeloid lineage progenitors give rise to vascular endotheliumProceedings of the National Academy of Sciences, 2006
- The interleukin-6/interleukin-6-receptorsystem is activated in donor heartsJACC, 2002
- Chemokines in ischemia/reperfusion injuryCurrent Opinion in Organ Transplantation, 2002